Proteo Biotech AG

Proteo, Inc. / Proteo Biotech AG: FDA grants Proteo Orphan Drug Designation to Elafin for the treatment of pulmonary arterial hypertension

Proteo, Inc. / Proteo Biotech AG: Update for Phase 2 Study of Elafin in Coronary Bypass Surgery (EMPIRE Study)

Proteo, Inc. / Proteo Biotech AG: Further rationale for Elafin treatment in newborn infants – convincing preclinical evidence in a neonatal pulmonary model

Proteo, Inc. / Proteo Biotech AG: Update for Phase 2 Study of Elafin in Coronary Bypass Surgery (EMPIRE Study)

Proteo, Inc./Proteo Biotech AG: Major advances in the elafin development program for lung diseases – NIH supports research on Elafin with a $10.8 million grant

Proteo, Inc. / Proteo Biotech AG: EMPIRE-Study recruits first coronary bypass patients

Proteo, Inc. / Proteo Biotech AG: Elafin shortens intensive care after surgery for esophagus cancer

Proteo, Inc./Proteo Biotech AG: Positive ethical opinion for the coronary bypass trial Phase II

Proteo, Inc./ Proteo Biotech AG: Proteo’s Elafin will be tested at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)

Proteo Inc./Proteo Biotech AG: Successful completion of patient recruitment for the Phase II clinical trial on Elafin in patients with esophagus cancer

Proteo Inc./Proteo Biotech AG: Orphan Drug Designation for Elafin in the Treatment of Oesophagus Carcinoma

Proteo Inc./Proteo Biotech AG: European Medicines Agency EMEA recommends orphan drug status for Elafin in the treatment of esophagus carcinoma

Proteo, Inc./ Proteo Biotech AG: Phase II clinical trial with Elafin for cardiovascular disease -University of Edinburgh and Proteo sign agreement

Proteo, Inc./Proteo Biotech AG: Clinical study in Harvard reveals Elafin deficiency in acute respiratory distress syndrome (ARDS)

Proteo Inc./Proteo Biotech AG – Minapharm/Rhein Minapharm Biogenetics SAE: Approval for a Phase II clinical trial with Elafin in kidney transplantation

Proteo, Inc./Proteo Biotech AG – Minapharm/Rhein Minapharm Biogenetics SAE: Zulassung für klinische Phase-II-Studie mit Elafin bei Nierentransplantationen

Proteo, Inc./Proteo Biotech AG: Start of the Phase II clinical trial with Elafin

Proteo, Inc./Proteo Biotech AG: Start der klinischen Phase-II-Studie mit Elafin

Proteo, Inc./Proteo Biotech AG: Proteo receives approval for Phase II clinical trial

Proteo, Inc./Proteo Biotech AG: Proteo erhält Zulassung für klinische Phase-II-Studie

Proteo, INC.: Proteo, Inc. also traded on the Berlin Stock Exchange

Proteo Biotech Inc.: Platzierung von Vorzugsaktien der Serie A – 3,6 Mio US$ zur Finanzierung klinischer Studien

Proteo, Inc.: Placement of Preferred Stock Series A – US$ 3.6 million finance for clinical trials

Proteo Inc./Proteo Biotech AG: Preclinical studies on pulmonary arterial hypertension – Proteo cooperates with Stanford University, USA

Proteo, Inc./Proteo Biotech AG – Minapharm/Rhein Minapharm Biogenetics SAE: Proteo Biotech, Germany and Minapharm, Egypt enter into development and license agreement for Elafin

Proteo, Inc./Proteo Biotech AG: Pulmonary diseases in newborns: Proteo cooperates with the University of Alberta

Proteo, Inc./Proteo Biotech AG:European Commission grants Orphan Drug Status to Elafin for the treatment of PAH

Proteo, Inc./ Proteo Biotech AG: European Medicines Agency EMEA recommends Orphan Drug Designation for Elafin

Proteo, Inc. / Proteo Biotech AG: Novel Anti-inflammatory Mechanism of Elafin

PROTEO Biotech AG/Kiel, PROTEO Inc./Irvine, CA: Elafin ranked as Top 10 Cardiovascular Drug Development